Mild-to-Moderate COVID-19 with SpO₂ >94% on Room Air When First-Line Antiviral Therapy Did Not Achieve Target Outcomes

This protocol applies to ambulatory patients with mild-to-moderate COVID-19 — SpO₂ above 94% on room air, not requiring supplemental oxygen — who are at high risk for progression to severe disease and for whom first-line therapy has not achieved the expected clinical targets.

Clinical Scenario

The patient is not hospitalised and does not currently require supplemental oxygen (SpO₂ >94% on room air), meeting the definition of mild-to-moderate COVID-19. Despite this, the clinical profile carries a high risk of deterioration to severe disease, making timely next-step management critical.

First-Line Failure Condition

Initial ambulatory management with nirmatrelvir/ritonavir, remdesivir, or anti-SARS-CoV-2 monoclonal antibodies was directed at avoiding COVID-19–related hospitalization and COVID-19–related medically attended visits through day 28. This protocol addresses the next step when those targets have not been met or those options are not available.

Next-Step Approach

The protocol specifies an antiviral approach initiated within a defined window from symptom onset, with a distinct alternative for patients who are immunocompromised. Full eligibility criteria, the complete regimen, and precise timing requirements are available in the structured protocol.

Goal: Avoidance of COVID-19–related hospitalization through day 29

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciac724

Mild-to-moderate illness is defined as patient with SpO₂ >94% not requiring supplemental oxygen.
In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.
In ambulatory patients (≥18 years) with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options, the IDSA guideline panel suggests molnupiravir initiated within 5 days of symptom onset rather than no molnupiravir.
Among ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease who have no other treatment options, the IDSA guideline panel suggests FDA-qualified high-titer COVID-19 convalescent plasma within 8 days of symptom onset rather than no high-titer COVID-19 convalescent plasma.

View source ↗